시장보고서
상품코드
1184169

MSC(Mesenchymal Stem Cells/Medicinal Signaling Cells) 시장 : 진보와 응용(2023년)

Mesenchymal Stem Cells / Medicinal Signaling Cells (MSCs) - Advances & Applications, 2023

발행일: | 리서치사: BioInformant Worldwide LLC | 페이지 정보: 영문 351 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 MSC(Mesenchymal Stem Cells/Medicinal Signaling Cells) 시장에 대해 조사했으며, 시장 개요와 함께 임상 상황, MSC가 취급하는 주요 질환 및 시장에 참여하는 기업 개요 등을 제공하고 있습니다.

목차

제1장 보고서 개요

제2장 중간엽줄기세포(MSC) : 개요

제3장 MSC에 관한 공개된 과학 논문

제4장 줄기세포 특허 상황 : 개요

제5장 MSC : 임상시험 상황

제6장 MSC의 기능을 높이는 바이오 엔지니어링 솔루션

제7장 MSC의 제조

제8장 MSC의 소규모 제조

제9장 MSC의 대규모 제조

제10장 세포 및 유전자 치료 수탁제조

  • 전문 지식을 가진 스탭의 필요성
  • 용량 제약
  • 최대 성장 가능성을 나타내는 CDMO 플랫폼
  • 세포 및 유전자 치료(CGT) 아웃소싱 동향
  • CMO/CDMO
  • 세계의 바이오프로세싱 능력
  • 2022년 세계의 상위 CDMO
  • 유럽의 세포 및 유전자 치료 수탁제조에서 영국의 독점 상태

제11장 MSC가 취급하는 주요 질환

  • 자가면역질환
  • 심혈관질환
  • 신경변성질환
  • 골 및 연골 질환
  • GvHD
  • 크론병
  • 1형 당뇨병
  • 전신홍반루푸스(SLE)
  • 파킨슨병(PD)
  • 알츠하이머병(AD)
  • 신부전
  • 척수 손상(SCI)
  • 만성 창상

제12장 중간엽줄기세포 산업 현황

  • 변경된 MSC 개요
  • 판매 승인을 받은 MSC 기반 제품
  • 현재 출시된 MSC 기반 골기질

제13장 MSC 부문의 최근 협업

제14장 시장 분석

제15장 기업 개요

  • 101 Bio
  • AbbVie, Inc
  • Abzena
  • Adipomics, Inc
  • Advancells
  • Advent BioServices, Ltd
  • Aegle Therapeutics
  • Aethlon Medical, Inc
  • AGC Biologics
  • AgeX Therapeutics, Inc.
  • AlloSource, Inc
  • Ambulero
  • American CryoStem Corporation
  • American Type Culture Collection(ATCC)
  • AMS Biotechnology, Ltd.(AMSBIO)
  • Andelyn Biosciences
  • Anemocyte S.r.l
  • Anterogen, Co., Ltd.
  • AQ Skin Solutions
  • Arranta Bio
  • Aruna Bio
  • Avid Bioservices, Inc
  • Bacthera
  • Baylx, Inc
  • BioCardia
  • BioCentriq
  • BioEden, Inc
  • Bioinova sro
  • BioRestorative Therapies
  • Bioscience Institute S.p.A
  • Bio-Techne
  • Blue Horizon International, LLC
  • Boehringer Ingelheim BioXcellence
  • Bonus Biogroup, Ltd
  • BrainStorm Cell Therapeutics
  • Caregen Nordic
  • CardioCell, LLC
  • Catalent Pharma Solutions
  • CCRM
  • Cellipont Bioservices
  • Celprogen, Inc
  • Celltex Therapeutics Corporation
  • Celltex Therapeutics Corporation
  • Cellular Biomedicine Group, Inc.
  • Citius Pharmaceuticals, Inc
  • Charles River Laboratories International, Inc.
  • Corestem, Inc
  • Creative Bioarray
  • Curia Global, Inc.
  • Cynata Therapeutics, Ltd.
  • Cytovance Biologics
  • Dendreon
  • Direct Biologics
  • ElevateBio
  • Exothera
  • EXOSOMEplus
  • FUJIFILM Cellular Dynamics, Inc.
  • Fujifilm Diosynth Biotechnologies
  • Future Cell Japan Co., Ltd
  • Genezen
  • Hope Biosciences, LLC
  • Invitrx Therapeutics
  • JCR Pharmaceuticals, Co., Ltd
  • Just-Evotec Biologics, Inc.
  • Kimera Labs, Inc
  • LifeCell
  • Longeveron
  • Lonza Group, Ltd.
  • Lorem Cytori USA, Inc
  • Lykan Bioscience
  • Matica Biotechnology, Inc
  • Medipost, Co., Ltd
  • Mesoblast, Ltd
  • MilliporeSigma
  • Novus Biologicals, LLC
  • NuVasive, Inc
  • Novus Biologicals, LLC
  • NuVasive, Inc
  • OCT Therapies & Research Pvt. Ltd.
  • Orthofix Medical, Inc.
  • Personal Cell Sciences, Corp
  • Personalized Stem Cells, Inc
  • Porton Advanced
  • Pluristem Therapeutics, Inc.
  • PromoCell GmbH
  • Regeneus, Ltd
  • Reliance Life Sciences Pvt. Ltd.
  • Rentschler Biopharma
  • Resilience
  • Richter-HELM
  • RoosterBio, Inc
  • RoslinCT
  • Samsung Biologics
  • Sentien Biotechnologies, Inc
  • Smith & Nephew plc
  • STEMCELL Technologies, Inc
  • Stemedica Cell Technologies, Inc.
  • Stemmatters
  • Stempeutics Research Pvt. Ltd
  • Syngene International Ltd
  • TaiwanBio Therapeutics, Co., Ltd.
  • Takeda Pharmaceutical Co., Ltd.
  • Symbiosis Pharmaceutical Services
  • Tempo Bioscience
  • Thermo Fisher Scientific
  • TranstoxBio
  • United Therapeutics Corporation
  • Viralgen
  • VIVEbiotech
  • Waisman Biomanufacturing
  • WuXi Biologics
  • Yapan Bio
  • Yposkesi
  • Zimmer Biomet Holdings, Inc.

그림 인덱스

KSM 23.03.17

Executive Summary

MSCs are multipotent cells that can differentiate into a variety of cell types, including but not limited to osteoblasts, chondrocytes, myocytes, and adipocytes. In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic. MSCs are advantageous over other cell types for a variety of reasons, including that they are immuno-evasive, making them an advantageous cell type for allogenic transplantation.

MSCs appear to be an exceptionally promising tool for cell therapy, because of their unusual advantages, which include availability, expandability, transplantability, and ethical implications. Interest in therapeutic applications of human MSCs arises from their diverse ability to impact human health, as well as their ability to migrate to sites of tissue injury/inflammation or tumor growth.

MSCs are essential raw materials for many regenerative medicine products, including cell-based therapies, engineered tissues, exosome products, cosmeceuticals, and cultured meat production. MSCs are also well-suited for use in the exponential growth field of 3D printing and numerous companies are working on manufacturing technologies to support the commercial-scale production of MSCs.

Today, numerous market competitors are also exploring commercialization strategies for MSC-derived extracellular vesicles (EVs) and exosomes, because these extracellular "packages" represent a novel strategy for accessing the therapeutic effects of MSCs without the risks of administering whole cells to patients. Gene editing of MSCs for overexpressing antitumor genes or therapeutic factors is broadening their application as well.

Despite the challenges associated with commercializing MSC-based therapeutics, there are more than 100,000 scientific publications published about MSCs and over 1,100 MSC-based clinical trials underway worldwide. Clinical trials involving MSC therapeutics have risen in recent years, in part due to trials related to COVID-19. Current "hotspots" for MSC clinical trials include the U.S., E.U., China, Middle East, and South Korea. While many early-stage MSC trials have demonstrated safety and efficacy, only a small number of MSC products have reached commercialization, indicating that the therapeutic market for MSCs remains early-stage. The first MSC-based cell therapy product was approved in 2010 in South Korea. To date, ten MSC-based cell therapy products have gained approval, as well as 19 MSC-based bone matrices.

While therapeutic success has been challenging, the demand for MSC-based research products has surged in recent years, with most large research product suppliers now offering a variety of MSC-based products, services, kits, and manufacturing tools. Major players involved in the market for MSC-based research products include Lonza, Thermo Fisher Scientific, Sigma Aldrich, VWR, Sartorius, ATCC, EMD Millipore, and others. Smaller and mid-sized players are also competing in this promising market, including but not limited to Axol Bioscience, StemBioSys, PromoCell, and iXCell Biotechnologies. To date, the company to establish itself with the greatest domain knowledge in the area of MSC-based products and manufacturing technologies is RoosterBio, headquartered in Frederick, Maryland, USA.

Cynata Therapeutics is also working diligently on technologies to enable large-scale production of MSC-based therapeutics, although it is exclusively focused on MSC-based therapeutics and is using its Cymerus™ platform technology to produce nearly infinite numbers of iPSC-derived MSCs. It is concurrently pursuing several clinical trials worldwide. In the coming years, an increasing number of research products and therapeutic products will continue to be developed around MSCs and their differentiated cell types.

Within this rapidly changing landscape, having a thorough understanding of the competition is essential. Therefore, this global strategic report details the activities of 113 leading MSC companies, including their core technologies and products under development. It presents detailed market size figures for the global MSC market, segmented by Geography and Business Segment, and accompanied by future forecasts through 2030.

This global strategic report includes:

  • Market size determination for the global MSC market, segmented by Geography and Business Segment
  • Future forecasts for the Global MSC Market through 2030
  • Major diseases addressed by MSCs in the ongoing clinical trials
  • Cost of manufacturing autologous and allogeneic MSCs
  • Rates, quantities, geographic locations, and types of MSC clinical trials
  • Types and sources of MSC industry funding
  • Detailed MSC patent analysis, including rates and geographic breakdown of MSC patents
  • The top owners, inventors, and sponsors of MSC patents
  • Recent business developments related to MSCs, including strategic collaborations and partnerships
  • MSC-based products with marketing approval and the companies commercializing them
  • Currently marketed MSC-based bone matrices
  • Pricing comparison of MSC-based products with marketing approval
  • The pipeline for MSC-based therapeutics
  • Emerging applications for MSCs, including genetic modification, 3D bioprinting, clean meat production, and cosmeceuticals
  • Company profiles for MSC market competitors, including their products, services, and technologies under development
  • Dozens of charts, figures, and tables
  • And so much more

In summary, this global strategic report presents market size figures with forecasts through 2030, as well as rates of MSC clinical trials, scientific publications, patents, funding events, and strategic collaborations. It also presents the pipeline for MSC-based therapeutics, identifies leading market competitors, and explores future directions for the industry at large. With the competitive nature of this global market, you don't have the time to do the research. Claim this report to become immediately informed, without sacrificing hours of unnecessary research or missing critical opportunities.

TABLE OF CONTENTS

1. REPORT OVERVIEW

  • 1.1. Statement of the Report
  • 1.2. Target Demographic
  • 1.3. Report Sources
  • 1.4. Purpose of the Report
    • 1.4.1. Survey Recent MSC Advancements
    • 1.4.3. Assess Opportunities for Commercialization
    • 1.4.4. Identify Major Market Players & Assess the Competitive Environment
    • 1.4.5. Identify Existing and Emerging Trends
    • 1.4.6. Identify Critical Opportunities and Threats within the MSC Market
  • 1.5. Executive Summary
  • 1.6. Introduction

2. MESENCHYMAL STEM CELLS (MSCS): AN OVERVIEW

  • 2.1. Stabilization of hMSCs as a Technology
  • 2.2. The Impact of MSCs on Regenerative Medicine
  • 2.3. Timeline of MSC Nomenclature
  • 2.4. Sources of MSCs
    • 2.4.1. Bone Marrow-Derived MSCs (BM-MSCs)
    • 2.4.2. Adipose-Derived MSCs (AD-MSCs)
    • 2.4.3. Umbilical Cord-Derived MSCs
  • 2.5. Cell Surface Markers in MSCs
  • 2.6. In Vitro Differentiation Potentials of MSCs
  • 2.7. Soluble Factors Secreted by MSCs
  • 2.8. Stemness Genes Present in MSCs

3. PUBLISHED SCIENTIFIC PAPERS ON MSCS

  • 3.1. Number of Papers on MSCs & iPSCs Compared
  • 3.2. Number of Papers Published on MSC-based Clinical Trials
  • 3.3. Number of Papers on Clinical Trials using MSCs for Specific Diseases
  • 3.4. Published Papers on Modified MSCs
  • 3.5. Published Papers on MSC-Derived Exosomes

4. STEM CELLS PATENT LANDSCAPE: AN OVERVIEW

  • 4.1. Geographical Distribution of Stem Cell Patent Filing
    • 4.1.1. Leading Players in Stem Cell Patent Arena
    • 4.1.2. Types of Patent Document Holders in Stem Cell Arena
    • 4.1.3. Top Ten Stem Cell Patent Owners by Size of Patent Portfolio
  • 4.2. MSC Patents
    • 4.2.1. Top Ten MSC Patent Applicants
    • 4.2.2. Status of MSC Patent Applications
    • 4.2.3. MSC Patent Jurisdictions
    • 4.2.4. Top Ten MSC Patent Inventors
    • 4.2.5. Top Ten MSC Patent Owners
    • 4.2.6. Patent Landscape of MSC-Derived Exosomes
    • 4.2.7. Number of Patent Applications by Year
    • 4.2.8. MSC-Exosomes Patent Jurisdiction
    • 4.2.9. Top Ten Patent Inventors

5. MSCS: CLINICAL TRIAL LANDSCAPE

  • 5.1. Analysis of Data from ClinicalTrials.gov
    • 5.1.1. Sources of MSCs for Clinical Trials
    • 5.1.2. Autologous vs. Allogeneic MSCs in Clinical Studies
    • 5.1.3. Types of Funding for MSC-based Clinical Trials
    • 5.1.4. Types of MSC-based Clinical Trials
    • 5.1.5. MSC-based Clinical Trials by Phase of Development
  • 5.2. Administration of MSCs in Clinical Trials
  • 5.3. MSC Clinical Trials by Disease Category
    • 5.3.1. MSC-based Clinical Trials for Musculoskeletal Disorders
    • 5.3.2. MSC-based Clinical Trials for Neurological Disorders
    • 5.3.3. Clinical Trials involving MSC-derived Exosomes

6. BIOENGINEERING SOLUTIONS TO BOOST MSC'S FUNCTIONS

  • 6.1. Small-Molecule Priming
  • 6.2. Particle Engineering
  • 6.3. Genetic Engineering
    • 6.3.1. Engineering MSCs to Go Beyond their Innate Functions
    • 6.3.2. Engineered MSCs for Neurological Conditions
    • 6.3.3. Engineered MSCs for Cardiovascular Diseases
    • 6.3.4. Engineered MSCs for Lung Injury
    • 6.3.5. Engineered MSCs for Diabetes
  • 6.4. Bioengineering Approaches to Improve MSC Administration

7. MANUFACTURING OF MSCS

  • 7.1. Autologous and Allogeneic MSCs
  • 7.2. Methods of Isolation of MSCs
  • 7.3. Cell Expansion: Conventional Cultures to Bioreactors
    • 7.3.1. Monolayer Culture Systems
    • 7.3.2. Bioreactor-Based Cell Expansion
      • 7.3.2.1. Stirred Tank Bioreactor
      • 7.3.2.2. Rocking Bioreactor
      • 7.3.2.3. Hollow Fiber Bioreactors
      • 7.3.2.4. Fixed-Bed Bioreactors
  • 7.4. Bioreactors in Current Use
    • 7.4.1. Miniaturized Bioreactors
    • 7.4.2. Alternative Mixing Mechanisms
  • 7.5. Main Features of Commercial Bioreactors
  • 7.6. Number of Cells per Batch by Technologies
  • 7.7. Microcarriers for the Expansion of MSCs
  • 7.8. Downstream Processing of MSCs
    • 7.8.1. Cell Detachment and Separation
    • 7.8.2. Cell Washing and Concentration
    • 7.8.3. Safety & Potency Assays
    • 7.8.4. Surface Markers for Identification during MSC Manufacture
  • 7.9. Autologous & Allogeneic MSC Manufacturing: A Comparison
    • 7.9.1. Manufacturing Cost: Autologous and Allogeneic MSCs
    • 7.9.2. Cost of Manufacturing Autologous MSCs
    • 7.9.3. Cost of Donor Screening & Testing
    • 7.9.4. Cost for Release Testing
  • 7.10. Cost Breakdown in MSC Manufacturing
    • 7.10.1. Strategies for Cost Reduction
      • 7.10.1.1. Cost of Manufacture in Partial Automation vs. Full Automation
      • 7.10.1.2. CoG Breakdown in Partially-Automated MSC Manufacturing
      • 7.10.1.3. CoG Breakdown in Fully Automated MSC Manufacturing
      • 7.10.1.4. Higher Throughput in Partially Automated Facilities

8. SMALL SCALE PROCESSING OF MSCS

  • 8.1. Model Design
  • 8.2. Culture Media

9. LARGE-SCALE MANUFACTURING OF MSCS

  • 9.1. The Four Common Bioprocessing Strategies for Large-Scale Expansion of MSCs
  • 9.2. Commonly Used Sources of MSCs for Large-Scale Expansion
  • 9.3. Commonly used Culture Media for Large-Scale Expansion of MSCs
    • 9.3.1. Expansion Ratios Achieved with Different Culture Media
  • 9.4. Comparison between the Four Large-Scale MSC Expansion Strategies

10. CONTRACT MANUFACTURING FOR CELL & GENE THERAPIES

  • 10.1. The Need for Staff with Expertise
  • 10.2. Capacity Constraints
  • 10.3. CDMO Platforms Showing Greatest Growth Potential
  • 10.4. Outsourcing Trends for Cell & Gene Therapies (CGT)
    • 10.4.1. Number of CDMOS Utilized by Biotechs
  • 10.5. CMOs/CDMOs
    • 10.5.1. Contract Manufacturing Organizations (CMOs)
      • 10.5.1.1. Major Services offered by CMOs
    • 10.5.2. Contract Development and Manufacturing Organizations (CDMOs)
  • 10.6. Global Bioprocessing Capacity
    • 10.6.1. Capacity Growth over Time
    • 10.6.2. Current Distribution of Capacity by Facility Size
    • 10.6.3. Global Bioprocessing Capacity by Region
  • 10.7. Top Global CDMOs in 2022
    • 10.7.1. Major Cell & Gene Therapy CDMOs in the U.S
    • 10.7.2. Major Cell & Gene Therapy Contract Manufacturers in Europe
  • 10.8. U.K.'s Domination in European Cell & Gene Therapy Contract Manufacturing
    • 10.8.1. Cell & Gene Therapy GMP Manufacturing in U.K.
    • 10.8.2. U.K. Cleanroom Footprint for CGT Manufacturing, 20018-2022
    • 10.8.3. Cell Therapy Process Capabilities in the U.K. by Types of Process
    • 10.8.4. Gene Therapy Process Capabilities in the U.K. by Types of Process
    • 10.8.5. Countries Importing Cell & Gene Therapy Services from U.K.

11. MAJOR DISEASES ADDRESSED BY MSCS

  • 11.1. Studies using MSCs for Autoimmune Diseases
  • 11.2. Studies using MSCs for Cardiovascular Diseases
  • 11.3. Studies using MSCs for Neurodegenerative Diseases
  • 11.4. Studies using MSCs for Bone & Cartilage Diseases
  • 11.5. Studies using MSCs in GvHD
  • 11.6. Studies using MSCs in Crohn's Disease
  • 11.7. Studies using MSCs in Type 1 Diabetes
  • 11.8. Studies using MSCS in Systemic Lupus Erythematosus (SLE)
  • 11.9. Studies using MSCs in Parkinson's disease (PD)
  • 11.10. Studies using MSCs in Alzheimer's Disease (AD)
  • 11.11. Studies using MSCs in Kidney Failure
  • 11.12. Studies using MSCs in Spinal Cord Injury (SCI)
  • 11.13. MSCs for Chronic Wounds

12. CURRENT STATUS OF MESENCHYMAL STEM CELL INDUSTRY

  • 12.1. Brief Account of Modified MSCs
    • 12.1.1. Genetic Modification of MSCs
    • 12.1.2. Priming of MSCs
      • 12.1.2.1. Primed MSCs in Clinical Trials
    • 12.1.3. Biomaterial Strategies
    • 12.1.4. MSC Secretomes
    • 12.1.5. MSCs in Topical Cosmetics
      • 12.1.5.1. Cosmetic Effects of Secretomes
      • 12.1.5.2. Secretome-Based Formulations for Skincare
  • 12.2. MSC-Based Products with Marketing Approval
    • 12.2.1. Alofisel
    • 12.2.2. Stemirac
    • 12.2.3. Stempeucel
    • 12.2.4. Temcell HS
    • 12.2.5. Neuronata-R
    • 12.2.6. Prochymal
    • 12.2.7. Cupistem
    • 12.2.8. Cartistem
    • 12.2.9. Cellgram-AMI
    • 12.2.10. Queencell
  • 12.3. Currently Marketed MSC-Based Bone Matrices
    • 12.3.1. Osteocel
    • 12.3.2. AlloStem
    • 12.3.3. Cellentra VCBM
    • 12.3.4. HiQCell
    • 12.3.5. Trinity ELITE
    • 12.3.6. Map3
    • 12.3.7. Trinity Evolution
    • 12.3.8. Carticel
    • 12.3.9. Chondron
    • 12.3.10. DeNovo
    • 12.3.11. Chondrocelect
    • 12.3.12. Ossron
    • 12.3.13. JACC
    • 12.3.14. MACI
    • 12.3.15. Ortho-ACI
    • 12.3.16. Spherox
    • 12.3.17. Ossgrow
    • 12.3.18. Cartigrow
    • 12.3.19. ViviGen
    • 12.3.20. Bio4
    • 12.3.21. Cartiform

13. RECENT COLLABORATIONS IN MSC SECTOR

  • 13.1. RoosterBio's Partnership with AGC Biologics
  • 13.2. RoosterBio's Partnership with ShiftBio
  • 13.3. Pluristem's Collaboration with Tnuva Group
  • 13.4. RoosterBio's Partnership with Univercells Technologies
  • 13.5. Partnership between Cynata & Fujifilm
  • 13.6. Collaboration between American CryoStem Corp. & BioTherapeutic Labs Corp
  • 13.7. RoosterBio's Partnership with Sartorius
  • 13.8. Research & Development Agreement between American CryoStem and CRADA
  • 13.9. RoosterBio's Partnership with Sartorius Korea Biotech
  • 13.10. Partnership between Catalent and BrainStorm
  • 13.11. Collaboration between Cipla & Stempeutics
  • 13.12. Aethlon's Collaboration with University of Pittsburgh
  • 13.13. RoosterBio's Partnership with Senti Biosciences

14. MARKET ANALYSIS

  • 14.2. Price Tags of MSC-Based CT Treatment
  • 14.3. Price Tags of MSC-Based Matrices
  • 14.4. Market Size of MSC-Based Therapies
  • 14.5. Global Market for MSC-Based Therapeutics
  • 14.6. Global Demand for Mesenchymal Stem Cells (MSCs)
    • 14.6.1. Global Demand for MSCs in Academic and Preclinical Studies
    • 14.6.2. Global Demand for MSCs in Clinical Trials
    • 14.6.3. Global Demand for MSCs for the Development of Therapeutics
    • 14.6.4. Global Demand for MSCs to Develop Exosome Products
    • 14.6.5. Global Demand for MSCs in Emerging Industries
    • 14.6.6. Global Market for MSCs
    • 14.6.7. Market Share of MSC-Based Business Segments

15. COMPANY PROFILES

  • 15.1. 101 Bio
    • 15.1.2. Products
    • 15.1.3. Services
  • 15.2. AbbVie, Inc.
    • 15.2.1. SkinMedica Neck Correct Cream
  • 15.3. Abzena
    • 15.3.1. Services
  • 15.4. Adipomics, Inc.
  • 15.5. Advancells
    • 15.5.1. MSC-Derived Exosome Therapy
  • 15.6. Advent BioServices, Ltd.
    • 15.6.1. Ultra Cold Storage Services
    • 15.6.2. Quality Control Services
  • 15.7. Aegle Therapeutics
    • 15.7.1. Aegle's Platform Technology
    • 15.7.2. Epidermolysis Bullosa
  • 15.8. Aethlon Medical, Inc.
    • 15.8.1. Hemopurifier in Infectious Disease
    • 15.8.2. Status of Clinical Studies
    • 15.8.3. Hemopurifier in Cancer
  • 15.9. AGC Biologics
    • 15.9.1. Offerings
  • 15.10. AgeX Therapeutics, Inc.
    • 15.10.1. Pluristem Technology
    • 15.10.2. Induced Tissue Generation
    • 15.10.3. UniverCyte
    • 15.10.4. HyStem Delivery Technology
  • 15.11. AlloSource, Inc.
    • 15.11.1. Allografts with Tissue-derived MSCs
    • 15.11.2. Products
      • 15.11.2.1. AlloConnex
      • 15.11.2.2. AlloFuse & AlloFuse Plus DBM
      • 15.11.2.3. AlloFlex Plus
      • 15.11.2.4. AlloFuse Cervical Grafts
      • 15.11.2.5. AlloFuse Fiber and Fiber Boats
      • 15.11.2.6. AlloFuse Select CM
  • 15.12. Ambulero
    • 15.12.1. Supercharged MSCs
    • 15.12.2. Ambulero's Pipeline
  • 15.13. American CryoStem Corporation
    • 15.13.1. Products
      • 15.13.1.1. CELLECT Tissue Harvesting System
      • 15.13.1.2. ACSelerateMAX hMSC Medium
      • 15.13.1.3. ATCELL Mesenchymal Stem Cells (ADSCs)
    • 15.13.2. Services
      • 15.13.2.1. ATGRAFT Fat Storage
      • 15.13.2.2. Adult Stem Cell Program
  • 15.14. American Type Culture Collection (ATCC)
    • 15.14.1. Stem Cell Products
  • 15.15. AMS Biotechnology, Ltd. (AMSBIO)
    • 15.15.1. Products
  • 15.16. Andelyn Biosciences
    • 15.16.1. Andelyn's Solutions
  • 15.17. Anemocyte S.r.l
    • 15.17.1. Total GMP Capacity
    • 15.17.2. Product Types
    • 15.17.3. Manufacturing Services
  • 15.18. Anterogen, Co., Ltd.
    • 15.18.1. Products
      • 15.18.1.1. Cupistem Injection
      • 15.18.1.2. Queencell Injection
  • 15.19. AQ Skin Solutions
    • 15.19.1. Products
      • 15.19.1.1. AQ Active Serum
      • 15.19.1.2. AQ Eye Serum
      • 15.19.1.3. AQ Lash
      • 15.19.1.4. AQ Vaginal Rejuvenation System
  • 15.20. Arranta Bio
    • 15.20.1. Services
  • 15.21. Aruna Bio
    • 15.21.1. AB126
  • 15.22. Avid Bioservices, Inc.
    • 15.22.1. Services
  • 15.23. Bacthera
    • 15.23.1. Services
  • 15.24. Baylx, Inc.
    • 15.24.1. Technology
    • 15.24.2. Rheumatoid Arthritis
    • 15.24.3. Metastatic Cancer
    • 15.24.4. FDA Clearance of IND Application
  • 15.25. BioCardia
    • 15.25.1. BioCardia's Pipeline Overview
      • 15.25.1.1. CardiAMP Cell Therapy
      • 15.25.1.2. CardiALLO Cell Therapy
  • 15.26. BioCentriq
    • 15.26.1. Clinical Manufacturing Services
    • 15.26.2. Process Development Services
  • 15.27. BioEden, Inc.
  • 15.28. Bioinova s.r.o
    • 15.28.1. MSCs for Clinical Trials
    • 15.28.2. Novel Solution for Storage and Transportation of Cells
  • 15.29. BioRestorative Therapies
    • 15.29.1. BRTX-100
    • 15.29.2. ThermoStem
  • 15.30. Bioscience Institute S.p.A
    • 15.30.1. LIPOSKILL
    • 15.30.2. HAIRSKILL
    • 15.30.3. GYNSKILL
    • 15.30.4. LIPOSKILL PLUS
  • 15.31. Bio-Techne
    • 15.31.1. Mesenchymal Stem Cell Products
  • 15.32. Blue Horizon International, LLC
    • 15.32.1. BHI's Stem Cell Division
  • 15.33. Boehringer Ingelheim BioXcellence
    • 15.33.1. Services
    • 15.33.2. Cell Line Development Services
  • 15.34. Bonus Biogroup, Ltd.
    • 15.34.1. BonoFill
    • 15.34.2. MesenCure
  • 15.35. BrainStorm Cell Therapeutics
    • 15.35.1. MSC-NTF Cells
  • 15.36. Caregen Nordic
    • 15.36.1. Dermaheal HSR
    • 15.36.2. Dermaheal HL
    • 15.36.3. Dermaheal SB
    • 15.36.4. Dermaheal Stem C'rum
    • 15.36.5. Dermaheal Stem C'rum SR
  • 15.37. CardioCell, LLC
    • 15.37.1. The itMSC Advantage
    • 15.37.2. Clinical Trials
  • 15.38. Catalent Pharma Solutions
    • 15.38.1. OneBio Integrated Suite
    • 15.38.2. Gene Therapy Services
    • 15.38.3. Cell Therapy Services
  • 15.39. CCRM
    • 15.39.1. CDMO Services
  • 15.40. Cellipont Bioservices
    • 15.40.1. Cellipont's Capabilities
    • 15.40.2. Cellipont's Cell Expertise
  • 15.41. Celprogen, Inc.
    • 15.41.1. Products
      • 15.41.1.1. FolliStem
      • 15.41.1.2. FolliStem Jawan
  • 15.42. CellResearch Corporation, Pte Ltd.
    • 15.42.1. Umbilical Cord Lining Stem Cells
  • 15.43. Celltex Therapeutics Corporation
    • 15.43.1. Therapy Services
  • 15.44. Cellular Biomedicine Group, Inc.
  • 15.45. Citius Pharmaceuticals, Inc.
    • 15.45.1. Stem Cell Platform
  • 15.46. Charles River Laboratories International, Inc.
    • 15.46.1. Products & Services
  • 15.47. Corestem, Inc.
    • 15.47.1. ALS (NeuroNata-R)
  • 15.48. Creative Bioarray
    • 15.48.1. MSC Services
      • 15.48.1.1. MSC Isolation and Expansion Services
      • 15.48.1.2. MSC Characterization Service
      • 15.48.1.3. MSC Differentiation Service
  • 15.49. Curia Global, Inc.
    • 15.49.1. Services
  • 15.50. Cynata Therapeutics, Ltd.
    • 15.50.1. Cymerus Platform
      • 15.50.1.1. Importance of Cymerus Technology
    • 15.50.2. Preclinical Development
      • 15.50.2.1. GvHD
      • 15.50.2.2. Critical Limb Ischemia
      • 15.50.2.3. Asthma
      • 15.50.2.4. Heart Attack
      • 15.50.2.5. Diabetic Wounds
      • 15.50.2.6. Coronary Artery Disease (CAD)
      • 15.50.2.7. Acute Respiratory Distress Syndrome (ARDS)
      • 15.50.2.8. Sepsis
      • 15.50.2.9. Osteoarthritis
  • 15.51. Cytovance Biologics
    • 15.51.1. CGMP Manufacturing
  • 15.52. Dendreon
    • 15.52.1. Provenge Immunotherapy
    • 15.52.2. Services
  • 15.53. Direct Biologics
    • 15.53.1. ExoFlo
  • 15.54. ElevateBio
    • 15.54.1. ElevateBio's Enabling Technologies
    • 15.54.2. BaseCamp cGMP
  • 15.55. Exothera
    • 15.55.1. Exoscan Process Analysis Services
    • 15.55.2. Process Design & Development Services
    • 15.55.3. GMP Manufacturing Services
  • 15.56. EXOSOMEplus
  • 15.57. FUJIFILM Cellular Dynamics, Inc.
    • 15.57.1. iCell Mesenchymal Stem Cells
  • 15.58. Fujifilm Diosynth Biotechnologies
    • 15.58.1. Cell & Gene Therapy Services
  • 15.59. Future Cell Japan Co., Ltd.
    • 15.59.1. BABY STEM
  • 15.60. Genezen
    • 15.60.1. Genezen's Capabilities
  • 15.61. Hope Biosciences, LLC
    • 15.61.1. Adult Stem Cell Banking
    • 15.61.2. Newborn Stem Cell Banking
    • 15.61.3. Hope Sponsored Clinical Trials
  • 15.62. Invitrx Therapeutics
    • 15.62.1. Reluma
  • 15.63. JCR Pharmaceuticals, Co., Ltd.
    • 15.63.1. TEMCELL HS Inj.
  • 15.64. Just-Evotec Biologics, Inc.
    • 15.64.1. J.POD Biomanufacturing Facility
    • 15.64.2. J.Design Solutions
    • 15.64.3. J.DISCOVERY - Molecule Discovery
    • 15.64.4. J.MD - Molecule Design
    • 15.64.5. JP3 - Process & Product Design
    • 15.64.6. J-POD - Manufacturing Design
  • 15.65. Kimera Labs, Inc.
    • 15.65.1. XoGlo
    • 15.65.2. XoGlo Pro
    • 15.65.3. Equisome HC
    • 15.65.4. Vive
      • 15.65.4.1. Effects of MSC Exosomes on Skin
  • 15.66. LifeCell
    • 15.66.1. Large-Scale Manufacturing of MSCs
  • 15.67. Longeveron
    • 15.67.1. Lomecel-B
    • 15.67.2. Focused Therapeutic Areas
      • 15.67.2.1. Hypoplastic Left Heart Syndrome (HLHS) Research Program
      • 15.67.2.2. Alzheimer's disease (AD) Research Program
      • 15.67.2.3. Aging Frailty Research Program
      • 15.67.2.4. Metabolic Syndrome Research Program
      • 15.67.2.5. Acute Respiratory Distress Syndrome (ARDS) Research Program
  • 15.68. Lonza Group, Ltd.
    • 15.68.1. Product Overview
      • 15.68.1.1. Poietics
      • 15.68.1.2. MSCGM Growth Medium
      • 15.68.1.3. TheraPEAK Growth Medium
      • 15.68.1.4. hMSC Chondrogenic Differentiation Medium
      • 15.68.1.5. hMSC Adipogenic Differentiation Medium
      • 15.68.1.6. ReagentPack Subculture Reagents
      • 15.68.1.7. Trypsin/EDTA for Mesenchymal Stem Cells
  • 15.69. Lorem Cytori USA, Inc.
    • 15.69.1. Celution System
  • 15.70. Lykan Bioscience
    • 15.70.1. Process Development
    • 15.70.2. Analytical Development
    • 15.70.3. Manufacturing Science & Technology
    • 15.70.4. Clinical & Commercial Manufacturing
    • 15.70.5. Supply Chain & Logistics
    • 15.70.6. Quality & Compliance
  • 15.71. Matica Biotechnology, Inc.
    • 15.71.1. Cell Line Development Services
    • 15.71.2. Process Development Services
    • 15.71.3. Assay Development Services
    • 15.71.4. GMP Production Services
    • 15.71.5. Product Release & Stability Testing
  • 15.72. Medipost, Co., Ltd.
    • 15.72.1. Products
      • 15.72.1.1. Cartistem
      • 15.72.1.2. Pneumostem
      • 15.72.1.3. SMUP-IA-01
      • 15.72.1.4. SMUP-IV-01
  • 15.73. Mesoblast, Ltd.
    • 15.73.1. Product Candidates
      • 15.73.1.1. Remestemcel-L
      • 15.73.1.2. Rexlemestrocel-L
  • 15.74. MilliporeSigma
    • 15.74.1. Cell Culture & Analysis Products
  • 15.75. NecstGen
    • 15.75.1. Cell Therapy Development & Manufacturing
    • 15.75.2. Viral Vector Development & Manufacturing
    • 15.75.3. Cleanroom Rental
  • 15.76. Novus Biologicals, LLC
  • 15.77. NuVasive, Inc.
    • 15.77.1. Osteocel Family
  • 15.78. OCT Therapies & Research Pvt. Ltd.
  • 15.79. Orthofix Medical, Inc.
    • 15.79.1. Trinity ELITE
    • 15.79.2. TrinityEvolution
  • 15.80. Personal Cell Sciences, Corp.
    • 15.80.1. Autokine CM
    • 15.80.2. Products
      • 15.80.2.1. U Autologous Adult Stem Cell Regenerative Firming Serum
      • 15.80.2.2. U Autologous Adult Stem Cell Regenerative Eye Cream
      • 15.80.2.3. U Autologous Adult Stem Cell Regenerative Moisturizer
  • 15.81. Personalized Stem Cells, Inc.
    • 15.81.1. Personalized Stem Cell Study: Knee Osteoarthritis
  • 15.82. Porton Advanced
  • 15.82.1 . Cell Therapy Services
    • 15.82.2. Portons LVV Services
  • 15.83. Pluristem Therapeutics, Inc.
    • 15.83.1. PLX Products
    • 15.83.2. PLX-PAD
      • 15.83.2.1. Mechanism of Action
    • 15.83.3. PLX-R18
      • 15.83.3.1. Mechanism of Action
    • 15.83.4. PLX-Immune
      • 15.83.4.1. Mechanism of Action
  • 15.84. PromoCell GmbH
    • 15.84.1. Human Stem & Blood Cell Culture Products
  • 15.85. Regeneus, Ltd.
    • 15.85.1. Technologies
      • 15.85.1.1. Progenza
        • 15.85.1.1.1. Mechanism of Action
      • 15.85.1.2. Sygenus
        • 15.85.1.2.1. Mechanism of Action
    • 15.85.2. Product Pipeline
  • 15.86. Reliance Life Sciences Pvt. Ltd.
    • 15.86.1. Regenerative Medicine Products
  • 15.87. Rentschler Biopharma
    • 15.87.1. Services
  • 15.88. Resilience
    • 15.88.1. Resilience's Capabilities
  • 15.89. Richter-HELM
    • 15.89.1. Services
  • 15.90. RoosterBio, Inc.
    • 15.90.1. RoosterBio's Technology
    • 15.90.2. Products
      • 15.90.2.1. Human Mesenchymal Stem Cells (hMSCs)
    • 15.90.3. Genetic Engineering Tools
      • 15.90.3.1. Genetic Engineering Media
      • 15.90.3.2. Cell Culture Media & Supplements
    • 15.90.4. Cell and Media Kits
    • 15.90.5. MSC-derived Exosomes
    • 15.90.6. cGMP CliniControl Products
    • 15.90.7. Process Development Services
    • 15.90.8. hMSC Analytical Services
  • 15.91. RoslinCT
    • 15.91.1. Services
      • 15.91.1.1. Process Development
      • 15.91.1.2. GMP Manufacturing
      • 15.91.1.3. Quality Control
      • 15.91.1.4. Quality & Regulations
      • 15.91.1.5. Product Storage & Logistics
    • 15.91.2. RoslinCT - Lykan Bioscience Combine
  • 15.92. Samsung Biologics
    • 15.92.1. Development Services
    • 15.92.2. Manufacturing Services
  • 15.93. Sentien Biotechnologies, Inc.
    • 15.93.1. SBI-101
      • 15.93.1.1. Prolonged Therapeutic Activity of MSCs in SBI-101
      • 15.93.1.2. Sentien's Product Pipeline
  • 15.94. Smith & Nephew plc
    • 15.94.1. Grafix
  • 15.95. STEMCELL Technologies, Inc.
    • 15.95.1. Products
      • 15.95.1.1. Mesenchymal Stem Cells (MSCs)
      • 15.95.1.2. Mesenchymal Stem and Progenitor Cell Research Products
  • 15.96. Stemedica Cell Technologies, Inc.
    • 15.96.1. BioSmart Technology
    • 15.96.2. Clinical Pipeline
  • 15.97. Stemmatters
  • 15.98. Stempeutics Research Pvt. Ltd.
    • 15.98.1. Stempeucel
      • 15.98.1.1. Process Description
    • 15.98.2. Stempeucare
    • 15.98.3. Cutisera
    • 15.98.4. Trichosera
    • 15.98.5. Perioptisera
  • 15.99. Syngene International Ltd.
    • 15.99.1. Services
  • 15.100. TaiwanBio Therapeutics, Co., Ltd.
  • 15.101. Takeda Pharmaceutical Co., Ltd.
    • 15.101.1. Alofisel (Darvadstrocel)
  • 15.102. Symbiosis Pharmaceutical Services
    • 15.102.1. Vial Filling Capability
    • 15.102.2. Drug Product Testing
    • 15.102.3. Qualified Person Release
    • 15.102.4. Clinical Labeling & Packaging
    • 15.102.5. Product Development
  • 15.103. Tempo Bioscience
    • 15.103.1. Products
      • 15.103.1.1. Human Cell Models
    • 15.103.2. Services & Alliances
  • 15.104. Thermo Fisher Scientific
    • 15.104.1. Cell Culture Services
    • 15.104.2. Cell Therapy Solutions
  • 15.105. TranstoxBio
    • 15.105.1. Products
      • 15.105.1.1. CarcinogenSAFE
      • 15.105.1.2. CardioSight
      • 15.105.1.3. HeMOToX
      • 15.105.1.4. HepatoSight
      • 15.105.1.5. NeuroSAFE
      • 15.105.1.6. SkinIR System
      • 15.105.1.7. TransD System
      • 15.105.1.8. Human Umbilical Cord Blood Monocytes
      • 15.105.1.9. Human Peripheral Blood CD34 Positive Cells
      • 15.105.1.10. CD34+ Configured Cellular Platform
      • 15.105.1.11. Human Mesenchymal Stem Cells
  • 15.106. United Therapeutics Corporation
    • 15.106.1. Genetically-Enhanced Mesenchymal Stem Cells (GEM)
  • 15.107. Viralgen
    • 15.107.1. Service
    • 15.107.2. Viralgen's Facilities
  • 15.108. VIVEbiotech
  • 15.109. Waisman Biomanufacturing
    • 15.109.1. GMP Cell Therapeutic Capabilities
    • 15.109.2. Cell Bank Specifics
    • 15.109.3. Waisman Products & Processes
  • 15.110. WuXi Biologics
    • 15.110.1. Manufacturing Services
  • 15.111. Yapan Bio
    • 15.111.1. Process Development Services
    • 15.111.2. Process Characterization Services
    • 15.111.3. GMP Manufacturing Services
  • 15.112. Yposkesi
  • 15.113. Zimmer Biomet Holdings, Inc.
    • 15.113.1. Cellentra VCBM

INDEX OF FIGURES

  • FIGURE 3.1: Number of Published Papers on MSCs between 2000 and 2022
  • FIGURE 3.2: Number of Papers on MSCs & iPSCs Compared
  • FIGURE 3.3: Number of Papers Published on MSC-based Clinical Trials, 2000-2022
  • FIGURE 3.4: Percent Share of Papers on Clinical Trials for Specific Diseases, 2000-2022
  • FIGURE 3.5: Number of Published Papers on Modified MSCs
  • FIGURE 3.6: Number of PubMed Papers on MSC-Exosomes
  • FIGURE 4.1: Number of Patent Documents in Stem Cell Therapies, 2011-2020
  • FIGURE 4.2: Geographical/Country Distribution of Stem Cell Patents
  • FIGURE 4.3: Types of Patent Document Holders in Stem Cell Arena
  • FIGURE 4.4: Number of MSC Patent Filings by Year, 2000-January 5, 2023
  • FIGURE 4.5: Number of MSC-Exosomes Patent Applications by Year, 2009 to Present
  • FIGURE 5.1: Number of Clinical Trials involving MSCs by Region
  • FIGURE 5.2: Sources of MSCs for Clinical Trials in 2022
  • FIGURE 5.3: Clinical Trials involving Autologous and Allogeneic MSCs in 2022
  • FIGURE 5.4: Types of Funding for MSC-based Clinical Trials
  • FIGURE 5.5: Types of MSC-based Clinical Trials
  • FIGURE 5.6: MSC-based Clinical Trials by Phase of Development
  • FIGURE 5.7: MSC Administration Routes
  • FIGURE 5.8: MSC Clinical Trials by Disease Category
  • FIGURE 6.1: Bioengineering Solutions to Boost the Functions of MSCs
  • FIGURE 6.2: Bioengineering Solutions for Improving Administration of MSCs
  • FIGURE 7.1: Advantages & Disadvantages of Autologous & Allogeneic MSCs
  • FIGURE 7.2: Monolayer Culture Systems
  • FIGURE 7.3: Stirred Tank Bioreactor
  • FIGURE 7.4: Rocking Bioreactor
  • FIGURE 7.5: Hollow Fiber Bioreactors
  • FIGURE 7.6: Fixed-Bed Bioreactors
  • FIGURE 7.7: Number of Cells per Batch by Technologies
  • FIGURE 7.8: Single-Use Harvestainer for Small Scale Application
  • FIGURE 7.9: Single-Use Harvestainer for Large Scale Application
  • FIGURE 7.10: Advantages & Disadvantages of Autologous and Allogeneic MSC
  • FIGURE 7.11: Cost of Goods (CoG) in MSC Manufacturing
  • FIGURE 7.12: Impact of Headcount on Overall CoG per Batch
  • FIGURE 7.13: CoG Breakdown in Partially-Automated MSC Manufacturing
  • FIGURE 7.14: CoG Breakdown in Fully Automated MSC Manufacturing
  • FIGURE 7.15: Higher Throughput in Partially Automated Facilities
  • FIGURE 8.1: Schematic of Sartorius' SelectT Automated Platform
  • FIGURE 8.2: Model of a Clean Room in a Small Scale Manufacturing Facility
  • FIGURE 9.1: Four Common Bioprocessing Strategies for Large-Scale Expansion of MSCs
  • FIGURE 9.2: Commonly Used Sources of MSCs for Large-Scale Expansion
  • FIGURE 9.3: Commonly used Culture Media for Large-Scale Expansion of MSCs
  • FIGURE 10.1: Outsourced Percent of CGT Manufacturing: Now and Five Years from Now
  • FIGURE 10.2: Number of CDMOs Utilized
  • FIGURE 10.3: Major Services offered by CMOs
  • FIGURE 10.4: Percentage of Total Biomanufacturing Capacity by Platform
  • FIGURE 10.5: Global Bioprocessing Capacity by Region/Country
  • FIGURE 10.6: U.K. Cleanroom Footprint for CGT Therapy Manufacturing, 20018-2022
  • FIGURE 10.7: Cell Therapy Process Capabilities in the U.K. by Types of Process, 2022
  • FIGURE 10.8: Gene Therapy Process Capabilities in the U.K. by Types of Process
  • FIGURE 11.1: Major Diseases Addressed by MSCs in Clinical Trials
  • FIGURE 11.2: Percent Share of Autoimmune Diseases Using MSCs in Clinical Trials
  • FIGURE 11.3: Percent Share of MSCs by Source in Trials for Cardiac Diseases
  • FIGURE 11.4: Percent Shares of Neurodegenerative Diseases in Clinical Trials using MSCs
  • FIGURE 11.5: % Shares of Studies using MSCs in Bone & Cartilage Diseases by Source
  • FIGURE 12.1: The Four MSC Modification Techniques
  • FIGURE 13.2: Priming Effects on MSCs
  • FIGURE 14.1: Percent Share of Marketed CT, GT and TE Products
  • FIGURE 14.2: Percent Market Share of CT Products by Indication
  • FIGURE 14.3: Global Market for MSC-Based Therapeutics by Geography
  • FIGURE14.4: Global Market for MSCs by Geography, 2022-2030
  • FIGURE 14.5: Market Share of MSCs by Business Segments
  • INDEX OF TABLES
  • TABLE 2.1: Timeline of MSC Nomenclature
  • TABLE 2.2: Sources of MSCs
  • TABLE 2.3: Advantages and Disadvantages of BM-MSCs
  • TABLE 2.4: Advantages and Disadvantages of AD-MSCs
  • TABLE 2.5: Advantages and Disadvantages of UC-MSCs
  • TABLE 2.6: Positive & Negative Markers in MSCs from different Sources
  • TABLE 2.7: In Vitro Differentiation Potentials of MSCs
  • TABLE 2.8: Soluble Factors Secreted by MSCs
  • TABLE 2.8: (CONTINUED)
  • TABLE 2.9: Some Typical Stemness Genes of MSCs
  • TABLE 3.1: Number of Published Papers on MSCs between 2000 to Present
  • TABLE 3.2: Number of Papers on MSCs & iPSCs Compared
  • TABLE 3.3: Number of Papers Published on MSC-based Clinical Trials, 2000 to Present
  • TABLE 3.4: Percent Share of Papers for Specific Diseases, 2000-2022
  • TABLE 3.5: Published Papers on Modified MSCs
  • TABLE 3.6: Number of PubMed Papers on MSC-Exosomes
  • TABLE 4.1: Number of Patent Documents in Stem Cell Therapies
  • TABLE 4.2: Top Ten Players in Stem Cell Patent Arena
  • TABLE 4.3: Top Ten Stem Cell Patent Owners by Size of Patent Portfolio
  • TABLE 4.4: Number of MSC Patent Filings by Year, 2000 to Present
  • TABLE 4.5: Top Ten MSC Patent Applicants
  • TABLE 4.6: Status of MSC Patent Applications, 2000-2022
  • TABLE 4.7: MSC Patent Jurisdictions
  • TABLE 4.7: (CONTINUED)
  • TABLE 4.8: Top Ten MSC Patent Inventors
  • TABLE 4.9: Top Ten MSC Patent Owners
  • TABLE 4.10: Top Ten MSC-Exosome Patent Applicants
  • TABLE 4.11: MSC-Exosomes Patent Jurisdiction
  • TABLE 4.12: Top Ten MSC-Exosome Patent Inventors
  • TABLE 5.1: Number of Clinical Trials involving MSCs by Region
  • TABLE 5.2: Sources of MSCs for Clinical Trials
  • TABLE 5.3: Clinical Trials involving Autologous and Allogneic MSCs in 2022
  • TABLE 5.4: Types of Funding for MSC-based Clinical Trials
  • TABLE 5.5: Types of MSC-based Clinical Trials
  • TABLE 5.6: MSC-based Clinical Trials by Phase of Development
  • TABLE 5.7: Examples of MSC-based Clinical Trials for Musculoskeletal Disorders
  • TABLE 5.7: (CONTINUED)
  • TABLE 5.8: MSC-based Clinical Trials for Neurological Disorders
  • TABLE 5.9: Clinical Trials involving MSC-derived Exosomes
  • TABLE 6.1: Examples of Bioengineered MSCs as Living Drug Factories
  • TABLE 6.2: Examples of Oncology Indications being studied using MSC Trojan Horses
  • TABLE 6.3: Select Cases of Modified MSC Applications & Therapeutic Outcome
  • TABLE 7.1: Methods of Isolation of MSCs & Corresponding Culture Media
  • TABLE 7.2: A Snapshot of Commercially Available Culture Systems
  • TABLE 7.2: (CONTINUED)
  • TABLE 7.2: (CONTINUED)
  • TABLE 7.2: (CONTINUED)
  • TABLE 7.2: (CONTINUED)
  • TABLE 7.3: Main Features of Commercially Available Bioreactors
  • TABLE 7.4: Microcarriers for the Expansion of MSCs
  • TABLE 7.4: (CONTINUED)
  • TABLE 7.5: Basic Assays for MSCs
  • TABLE 7.6: Cell Surface Markers on MSCs and Fibroblasts
  • TABLE 7.7: Cost of Manufacturing Allogeneic MSCs
  • TABLE 7.8: Cost of Manufacturing Autologous MSCs
  • TABLE 7.9: Cost of Goods (CoG) in MSC Manufacturing
  • TABLE 7.10: CoG Breakdown in Partially-Automated MSC Manufacturing
  • TABLE 7.11: CoG Breakdown in Fully Automated MSC Manufacturing
  • TABLE 7.12: Higher Throughput in Partially Automated Facilities
  • TABLE 8.1: Key Processes and Cost Assumptions
  • TABLE 8.2: Quality Control Panels and Cost Assumptions
  • TABLE 8.3: Additional Supporting Labor Cost Assessments
  • TABLE 8.3: (CONTINUED)
  • TABLE 8.4: Additional Supporting Facility and Cost Assumptions
  • TABLE 8.4: (CONTINUED)
  • TABLE 9.1: Large-Scale Expansion of MSCs by Method, Cell Source and Media
  • TABLE 9.1: (CONTINUED)
  • TABLE 9.2: Expansion Ratios Achieved with Different Culture Media
  • TABLE 9.3: Comparison between the Four Large-Scale MSC Expansion Strategies
  • TABLE 10.1: Comparison of Capacity Trends, 2018-2021
  • TABLE 10.2: Current Distribution of Capacity by Facility Size
  • TABLE 10.3: Global Bioprocessing Capacity by Region/Country
  • TABLE 10.4: Top Global CDMOs
  • TABLE 10.5: GMP Capacities of U.S-based Contract Manufacturers
  • TABLE 10.6: Major Cell & Gene Therapy Contract Manufacturers in Europe
  • TABLE 10.7: GMP Manufacturing Facilities for Cell and Gene Therapies in U.K., 2022
  • TABLE 10.7: (CONTINUED)
  • TABLE 10.8: U.K. Cleanroom Footprint for Cell & Gene Therapy Manufacturing, 20018-2022
  • TABLE 10.9: Countries Outsourcing Cell & Gene Therapy Services from U.K. by Country
  • TABLE 11.1: Select MSC-Based Clinical Trials for Autoimmune Diseases
  • TABLE 11.2: Select MSC-Based Clinical Trials for Cardiovascular Studies
  • TABLE 11.3: Select MSC-Based Studies using MSCs for Neurodegenerative Diseases
  • TABLE 11.4: Select MSC-Based Studies for Bone & Cartilage Diseases
  • TABLE 11.5: Ongoing Studies using MSCs for GvHD
  • TABLE 11.6: Examples of Ongoing Clinical Trials using MSCs for Crohn's Disease
  • TABLE 11.7: Examples of Ongoing Clinical Trials using MSCs for Type 1 Diabetes
  • TABLE 11.8: Examples of Currently Ongoing Clinical Trials using MSCs for SLE
  • TABLE 11.9: Examples of Ongoing Clinical Trials using MSCs for PD
  • TABLE 11.10: Examples of Currently Ongoing Clinical Trials using MSCs for AD
  • TABLE 11.11: Examples of Ongoing Clinical Trials using MSCs for Kidney Failure
  • TABLE 11.12: Examples of Ongoing Clinical Trials using MSCs for SCI
  • TABLE 11.13: Examples of Currently Ongoing Clinical Trials using MSCs for SCI
  • TABLE 12.1: Clinical Trials Involving Engineered MSCs
  • TABLE 12.2: Primed MSCs in Clinical Trials
  • TABLE 12.3: Scaffold-Based MSCs in Clinical Trials
  • TABLE 12.3: (CONTINUED)
  • TABLE 12.4: Clinical Trials Involving MSC-Derived Exosomes
  • TABLE 12.5: Commercially Available Products Incorporated with Secretomes
  • TABLE 12.5: (CONTINUED)
  • TABLE 12.5: (CONTINUED)
  • TABLE 12.6: MSC Products with Marketing Approval
  • TABLE 12.6: (CONTINUED)
  • TABLE 12.7: Marketed MSC-Containing Bone Matrices
  • TABLE 14.1: Price Tags of MSC-Based Approved CT Products
  • TABLE 14.2: Price Tags of Select MSC Progenitor-Based Products
  • TABLE 14.3: Global Market for MSC-Based Therapeutics
  • TABLE 14.4: Global Market for MSCs by Geography, 2022-2030
  • TABLE 15.1: Ambulero's Product Pipeline
  • TABLE 15.2: BioCardia's Advanced Pipeline
  • TABLE 15.3: Bonus Biogroup's Product Pipeline
  • TABLE 15.4: BrainStorm's Product Pipeline
  • TABLE 15.5: CardioCell's Clinical Development
  • TABLE 15.6: Celltex's Clinical Trials
  • TABLE 15.7: Corestem's Product Pipeline
  • TABLE 15.8: Cynata's Product Pipeline
  • TABLE 15.9: Regulatory Proteins found in ExoFlo
  • TABLE 15.10: Hope's Clinical Trial Pipeline
  • TABLE 15.11: Growth Factors in XoGlo and XoGlo Plus
  • TABLE 15.12: Mesoblast's Late-Stage Clinical Pipeline
  • TABLE 15.13: Pluristem's Clinical Pipeline
  • TABLE 15.14: Regeneus' Product Pipeline
  • TABLE 15.15: Sentien's Product Pipeline
  • TABLE 15.16: Stemedica's Clinical Pipeline
  • TABLE 15.17: Stempeutics' Product Candidates in Clinical Trial
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제